Compare WTRG & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTRG | ARWR |
|---|---|---|
| Founded | 1901 | 2003 |
| Country | United States | United States |
| Employees | 1615 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 10.2B |
| IPO Year | 1994 | 2009 |
| Metric | WTRG | ARWR |
|---|---|---|
| Price | $37.20 | $73.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $43.50 | ★ $83.40 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | 1.38 | ★ 99.80 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $2,474,615,000.00 | $16,142,321.00 |
| Revenue This Year | $5.07 | N/A |
| Revenue Next Year | $7.31 | N/A |
| P/E Ratio | $46.51 | ★ N/A |
| Revenue Growth | ★ 18.62 | N/A |
| 52 Week Low | $36.11 | $14.30 |
| 52 Week High | $42.37 | $82.26 |
| Indicator | WTRG | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 46.21 |
| Support Level | $36.78 | $70.49 |
| Resistance Level | $40.35 | $77.39 |
| Average True Range (ATR) | 0.78 | 3.63 |
| MACD | 0.12 | -0.89 |
| Stochastic Oscillator | 86.15 | 26.81 |
Essential Utilities is a Pennsylvania-based holding company for US water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Its largest service territory is in Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. It completed the sale of its West Virginia gas utility and the bulk of its nonregulated assets in 2024. Essential shareholders would own a 31% stake in American Water Works if the proposed all-stock merger closes in 2027.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.